[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Nautilus Biotechnology, Inc. director and CEO Sujal M. Patel reported an open-market purchase of 25,000 shares of Common Stock at a weighted average price of $2.6095 per share. Following this buy, he directly owns 10,366,721 common shares.

He also reports indirect ownership of 5,280,476 common shares held by PFV I, LLC, for which he is the manager, and 1,814,035 common shares held by the Sujal Patel 2020 Children's Trust, where he and his spouse serve as trustees.

Insider Trade Summary

Net Buyer: 25,000 shares ($65,238)

Net Buy 3 txns

Insider Patel Sujal M

Role CEO, President, and Secretary

Bought 25,000 shs ($65K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	25,000	$2.6095	$65K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 10,366,721 shares (Direct); Common Stock — 5,280,476 shares (Indirect, By PFV I, LLC)

Footnotes (1)

1. Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC. Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Sujal M

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, President, and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		P		25,000	A	$2.6095(1)	10,366,721	D
Common Stock								5,280,476	I	By PFV I, LLC(2)
Common Stock								1,814,035	I	By Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

2. Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC.

3. Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust.

Remarks:

	/s/ Matthew Murphy, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.